Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial

已完结 10 由得得七七发布于 2025/7/6 21:53:43

DOI:10.1016/s0140-6736(25)00721-4
作者：Ashish Sarraju, Danielle Brennan, Kierstyn Hayden, Amanda Stronczek, Anne C Goldberg, Erin D Michos, Darren K McGuire, Denise Mason, Grace Tercek, Stephen J Nicholls, Douglas Kling, Annie L Neild, Joh
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundReducing LDL cholesterol prevents atherosclerotic cardiovascular disease (ASCVD) events. The aim of this study was to evaluate the LDL cholesterol-lowering efficacy of a fixed-dose

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Karger PublishersAssociation of Differences in Estimated Glomerular Filtration Rate by Cystatin C Versus Creatinine with Adverse Events in Adults Undergoing Major Surgery: a Multicenter Cohort Study.